After experiencing multiple negative factors, the stock price has halved in two months. Has Legend Biotech Corp. Sponsored ADR (LEGN.US) discovered a valuation trap or a golden opportunity?

What was initially thought to be a "40cm" big bullish candle marking the start of a new valuation rebound turned out to be the final chapter of the previous round of stock price rebounds. After spending two months bringing the stock price back to a high of $37.50, Legend Biotech Corp. Sponsored ADR (LEGN.US) spent another two months dropping the stock price back below $20, erasing all gains made in April and May. It was observed that after hitting a temporary high of $37.50 during intraday trading on June 3, Legend Biotech Corp. Sponsored ADR experienced a technical pullback over three trading days due to overbought signals; however, market sentiment remained relatively high. On June 8, before hitting the middle Bollinger Band, the companys stock formed a long lower shadow and subsequently, supported by buying pressure, posted a three-day bullish run. Just when investors believed that Legend Biotech Corp. Sponsored ADR's stock was poised to break out above previous highs in a trending upward correction, three consecutive negative news events within a two-month span abruptly interrupted its upward momentum, resulting in the stock price ultimately giving back all gains from the previous two months, with a peak drop of 51.12%. From discounted secondary offerings to CEO resignations During the downturn of Legend Biotech Corp. Sponsored ADR between June 16 and August 3 of this year, there were three significant price drop points, occurring on June 18, July 15, and July 27. These three points correspond directly with three negative events that surfaced during this timeframe. On June 18, Legend Biotech Corp. Sponsored ADR's stock price plummeted 16.68% in a single day, closing at $27.93. The market capitalization fell from $6.226 billion to $5.188 billion in one trading day, evaporating nearly $1 billion. Just days earlier, on June 14, Legend Biotech Corp. Sponsored ADR had announced impressive data on its in-body CAR-T therapy LB2501 for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) at the EHA Annual Meeting, revealing an ORR of 100% (6/6) and a CR of 83.3% (5/6). This early clinical data was already considered top-tier in the NHL CAR-T field. Such excellent clinical results instilled confidence in Legend Biotech Corp. Sponsored ADRs potential to unlock a second growth curve, but it also led to a crucial factor that surged the stock price of Legend Biotech Corp. Sponsored ADR a discounted secondary offering. Pre-market on June 18, Legend Biotech Corp. Sponsored ADR announced a public offering of 7.7 million ADS shares at $29.35 each (a 12.4% discount from the previous days closing price of $33.52), raising approximately $226 million. The underwriters were also granted a 30-day option to purchase up to an additional 15% of the shares. The stated purpose for the secondary offering was clear to fund pipeline research and development. Considering that its core commercial product, Carvykti, was in a ramp-up phase alongside the recent disclosure of the in vivo CAR-T products excellent data, this offering was essentially a signal to accelerate pipeline development focused on LB2501, aiming to forge a second growth curve for the company. However, despite the fantastic clinical data, U.S. stock investors remained unconvinced. The reasons were twofold: one was that the 2025 annual report indicated the company had cash on its books of $835 million, and it expected to become profitable in 2026; the second was that with the H1 2026 earnings report impending, the company opted for a more than 10% discounted secondary offering for pipeline development, an action clearly detrimental to market sentiment. Consequently, on June 18, Legend Biotech Corp. Sponsored ADRs stock plunged to open lower and continued to decline, ultimately closing at $27.93, below the offering price. From a volume perspective, on June 18, Legend Biotech Corp. Sponsored ADR recorded a trading volume of 13.6084 million shares, indicating sharp trading activity that pointed to a significant divide in sentiment regarding the company's discounted secondary offering. The comparison of the chip distribution between June 17 and 18 showed a reduction in positions above the $34.90 resistance level, but an increase in chip volume around the $27.93 level, indicating that many investors chose to bottom-fish during the downturn, supported by expectations of the core commercialization product, Carvykti, ramping up in Q2 2026. However, the market sentiment shifted following the July 27 announcement of CEO Huang Yings resignation from his position as Chief Executive Officer and Director at Legend Biotech Corp. Sponsored ADR. At that time, Johnson & Johnson had reported Carvyktis Q2 2026 earnings: $657 million in sales, a year-on-year increase of 49.4%; cumulative sales in the first half of the year reached $1.254 billion, soaring 55.1%. This meant that despite numerous previous market doubts, the drug continued to see accelerating sales. The resignation of the CEO had a considerable impact on the short-term market for Legend Biotech Corp. Sponsored ADR because Huang Ying was a key figure in steering the company through its transition from clinical to global commercialization. The exit of such a crucial management role affected investor confidence significantly, as reflected in the trading volume dynamics and chip distribution in the secondary market. On July 27, Legend Biotech Corp. Sponsored ADR saw another trading volume of over 10 million shares, hitting 10.0709 million shares that day. While the company's stock opened lower and continued to decline, previously concentrated chips in the $27.60-$29 range were notably reduced, accompanied by a surge in chips above $21.37 and at the bottom around $18. Was Johnson & Johnson's stance a key factor in influencing market confidence? During the recent downturn of Legend Biotech Corp. Sponsored ADRs stock, the two major negative factors driving the gap down were undoubtedly the discounted secondary offering and the CEO resignation. However, between these two events, the Q2 earnings report from partner Johnson & Johnson and their comments during the earnings call were also key elements affecting market confidence in Legend Biotech Corp. Sponsored ADR. On July 15, within an hour of trading, Legend Biotech Corp. Sponsored ADR's stock saw its decline accelerate, with reductions dropping towards 10% from the opening level near breakeven, followed by continued low-level fluctuations, ultimately closing down 10.25%. On that same day, Johnson & Johnson announced its Q2 2026 earnings, disclosing $657 million in global sales for Carvykti during the quarter. This performance largely met prior market expectations. A major reason for Legend Biotech Corp. Sponsored ADR's substantial drop may be attributed to a comment made by a Johnson & Johnson executive during the earnings call: that Johnson & Johnsons own dual anti-CD3/BCMA antibody combination, Tecvayli + Darzalex, shows potential for cure in second-line multiple myeloma. The implication was clear: in Johnson & Johnsons competitive landscape for second-line multiple myeloma treatments, Tecvayli + Darzalex stood at a similar position to Carvykti, significantly undermining market expectations for Carvykti's exclusivity. This wasnt the first time Legend Biotech Corp. Sponsored ADR had been caught off guard by a partner. Back in early December last year, as Legend Biotech Corp. Sponsored ADR was starting a rebound, a crushing blow from partner Johnson & Johnson struck at a critical moment. On December 9 of last year, Johnson & Johnson presented clinical data at the 2025 ASH Meeting regarding its self-developed BCMA/CD3 dual antibody (Tecvayli) combined with the CD38 monoclonal antibody (Darzalex) from its Phase 3 MajesTEC-3 trial. In terms of major clinical endpoints, the Tec-Dara United Therapeutics Corporation group achieved a 36-month PFS rate of 83.4%, while the control group (DPd/DVd) reached 29.7%, with a median PFS of 18.1 months in the control group, and the Tec-Dara United Therapeutics Corporation group has not yet reached the endpoint, resulting in an HR of 0.17, significantly mitigating disease progression. Notably, compared to the Legendary BCMA CAR-T drug Carvykti, the similar study CARTITUDE-4 set to be released in 2024 has a 30-month median PFS rate of 59.4% over a 34-month long-term follow-up, evidently lower than Tec-Dara's results from the United Therapeutics Corporation group. Additionally, concerning the residual disease negativity rate, Tec-Daras results remained consistent with Carvykti's response rates of 84.6% and OS rates of 76.4%. In this context, since the Tec-Dara United Therapeutics Corporation group represents an existing product while being a 100% asset of Johnson & Johnson, there are market concerns about potential biases in favor of this combined therapy due to "interest-driven resource allocation," which has been one of the reasons affecting the valuation of Legend Biotech Corp. Sponsored ADR and subsequently leading to its stock decline. However, from a market standpoint, Carvykti represents a one-time cell therapy option while Tecvayli + Darzalex offers a continuous treatment solution, indicating a clear distinction in patient demographics. Both Carvykti and the Tec-Dara United Therapeutics Corporation group serve as strategic components in Johnson & Johnsons multiple myeloma portfolio, and the enhancement of both products is crucial for solidifying Johnson & Johnson's market advantage. As one of Johnson & Johnson's management representatives clearly indicated during the call: the goal is to have approximately 80% of multiple myeloma patients use at least one Johnson & Johnson product during their therapy. Thus, while sustaining a approximately 50% quarterly sales growth, Carvykti remains one of Johnson & Johnson's fastest-growing oncology assets in the multiple myeloma landscape, providing them with no incentive to undermine its commercialization potential. From Legend Biotech Corp. Sponsored ADR's perspective, after experiencing a significant drop, the current market-to-sales ratio valuation stands at just 3.51 times, significantly lower than the industry average of 9.47 times, retaining substantial attractiveness for long-term optimistic investors.